Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.

Cabergoline, an ergot-derived dopamine receptor agonist, is used widely in the treatment of Parkinson's disease (PD) and hyperprolactinemia, but may cause heart valve fibrosis, retraction, and clinically significant regurgitation in PD patients. While cabergoline has been used at much lower doses in patients with hyperprolactinemia, controversy persists as to whether it may cause heart valve disease in this situation. Cabergoline is also used in acromegaly at doses similar to those used in hyperprolactinemia. The case is reported of a female patient with acromegaly who had been taking low-dose (0.5 mg/day) cabergoline for one year, and presented with signs and symptoms of right-sided heart failure. Echocardiography revealed a thickened and retracted tricuspid valve associated with severe tricuspid regurgitation and enlargement of the right-heart chambers. The morphology of the tricuspid valve was typical for cabergoline-related valvulopathy. Cabergoline may not be totally safe even at lower doses, and close echocardiographic monitoring is recommended in patients receiving cabergoline treatment, regardless of the dose level employed.

[1]  T. Cawood,et al.  Low‐dose cabergoline causing valvular heart disease in a patient treated for prolactinoma , 2009, Internal medicine journal.

[2]  Elena S. Di Martino,et al.  Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies , 2008, Journal of endocrinological investigation.

[3]  Jeroen J. Bax,et al.  Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. , 2008, European journal of endocrinology.

[4]  W. Poewe,et al.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.

[5]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[6]  W. Haverkamp,et al.  Dopamine agonists and the risk of cardiac-valve regurgitation. , 2007, The New England journal of medicine.

[7]  P. Marcos-Alberca,et al.  Cabergoline-related severe restrictive mitral regurgitation. , 2005, The New England journal of medicine.

[8]  A. Lang,et al.  Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists , 2004, Movement disorders : official journal of the Movement Disorder Society.

[9]  Jeroen J. Bax,et al.  Increased prevalence of regurgitant valvular heart disease in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  W. Edwards,et al.  Valvular heart disease in patients taking pergolide. , 2002, Mayo Clinic proceedings.